What to expect with the global prediabetes market

Emerging technologies are expected to drive market growth.

The prediabetes market is projected to see moderate growth by 2034, signifying a change in its dynamics in the coming years, according to a DelveInsight report.

The report revealed that the market is being driven by increased public awareness, improved access to health services, and rising obesity rates.

However, there is a huge unmet need in the market for approved therapies for effective treatment.

“Type 2 diabetes (T2D) drugs, effective in treating prediabetes, highlight an unmet need, as there is no approved treatment for prediabetes, creating an opportunity for new players and opening a platform for new therapies to boost the market of the indication,” The report said.

Meanwhile, potential therapies are currently being investigated for treatment, further impacting the market within the forecast period. 

“The anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the prediabetes market in the 7MM,” It added.

However, DelveInsight noted that the market is also challenged by several factors, impeding its growth.

The demand for therapeutics may be affected by misdiagnosis and patient confusion due to a lack of uniform classification and diagnostic criteria whilst off-label usage may hinder the uptake of novel therapies.

Moreover, the market’s expansion may be affected by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists.